Active, Not Recruiting
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Led by Weill Medical College of Cornell University · Updated on 2026-06-17
15
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
Sponsors
W
Weill Medical College of Cornell University
Lead Sponsor
E
Epizyme, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.
CONDITIONS
Brief Title
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- Confirmed diagnosis of DLBCL, FL, or MCL
- Eligible to receive standard of care CAR T cells
- Have received at least 1 prior therapies
Exclusion Criteria:
- Active viral infection with HIV or hepatitis type B or C
- Active, uncontrolled systemic fungal, bacterial or viral infection
- Active treatment for another cancer
- Pregnant or breastfeeding
- Unable to take oral medication
- Certain significant past medical history, such recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here